IFNG and cancer: While IFNG.GS gene signature in T cells could be used to predict the prognosis of cancer patients treated with ICBT9; interestingly, we found that genes consistently selectively upregulated during chronic IFNγ exposure in our YUMM2.1 and CT26 tumour models predicted shorter survival of metastatic urothelial cancer patients treated with α-PD-L1 therapy.